Editas Medicine, Inc.

What does it do?

Editas Medicine is a biotech company trying to fix diseases by editing the DNA inside human cells — think of it like using a molecular pair of scissors (called CRISPR) to cut out or repair faulty genetic instructions. Their main focus right now is a treatment called EDIT-401, which targets high LDL cholesterol — the 'bad' cholesterol that clogs arteries — by tweaking a gene in the liver to help the body clear it more effectively. They are also working on treatments for sickle cell disease, a painful inherited blood disorder, and beta thalassemia, another inherited condition where the body can't make healthy red blood cells properly. These are all 'one and done' therapies — the idea is that a single treatment could fix the problem permanently, rather than taking a pill every day.

How does it make money?

Editas currently generates almost no revenue in the traditional sense — it is a clinical-stage company, meaning its drugs are still being tested and haven't been approved for sale yet. Its income comes almost entirely from collaboration agreements and grants, where larger pharmaceutical companies or government bodies pay Editas for access to its technology or research expertise. The company reported roughly $0 in product revenue and posted a net loss of around $200 million last year, which means it is burning through its cash reserves to fund research. This is normal for early-stage biotechs, but it means investors are essentially betting on future drug approvals, not current profits.

Why do investors care?

The big dream here is that one or more of Editas's gene-editing therapies gets approved and becomes a blockbuster drug — a single approved gene therapy can generate hundreds of millions or even billions in revenue annually given how rare and severe these diseases are. EDIT-401 for high cholesterol is particularly interesting because high cholesterol is one of the most common health problems on the planet, meaning the market opportunity is enormous if the drug proves safe and effective. For the thesis to work, Editas needs its clinical trials to produce clean safety and efficacy data, and it needs to extend its cash runway long enough to reach those milestones — both are uncertain right now. Investors are essentially buying a lottery ticket on cutting-edge science at a very low price.